These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16163428)

  • 1. [Activity of cefpodoxime against pathogens causing respiratory, urinary or soft tissue infections].
    Silva F; Durán C; Ulloa MT; Prado V
    Rev Med Chil; 2005 Aug; 133(8):903-10. PubMed ID: 16163428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
    Hsueh PR; Huang WK; Shyr JM; Lau YJ; Liu YC; Luh KT
    J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.
    Knothe H; Shah PM; Eckardt O
    Infection; 1991; 19(5):370-6. PubMed ID: 1800379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibacterial activity of oral antibiotics against community-acquired respiratory pathogens from three European countries.
    Schito GC; Georgopoulos A; Prieto J
    J Antimicrob Chemother; 2002 Jul; 50 Suppl():7-11. PubMed ID: 12077154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
    Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME
    Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of cefpodoxime against pathogens responsible for community-acquired respiratory tract infections.
    Dabernat H; Avril JL; Boussougant Y
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():1-6. PubMed ID: 2127267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime+clavulanic acid among beta-lactamase positive clinical isolates of gram-positive and gram-negative pathogens.
    Pal RB; Pal P; Jain S; Kulkarni KP
    J Indian Med Assoc; 2008 Aug; 106(8):545-8. PubMed ID: 18975519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro evaluation of cefpodoxime.
    Valentini S; Coratza G; Rossolini GM; Massidda O; Satta G
    J Antimicrob Chemother; 1994 Mar; 33(3):495-508. PubMed ID: 8040114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibility of pathogens isolated from more than 10,000 patients with infectious respiratory diseases: a 25-year longitudinal study.
    Goto H; Shimada K; Ikemoto H; Oguri T;
    J Infect Chemother; 2009 Dec; 15(6):347-60. PubMed ID: 20012724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM; Suter M; Borsos S
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics.
    Kayser FH
    Infection; 1994; 22(5):370-5. PubMed ID: 7843823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients.
    Sultan T; Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(2):80-91. PubMed ID: 8131638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens' antibacterial susceptibility.
    Niki Y; Hanaki H; Matsumoto T; Yagisawa M; Kohno S; Aoki N; Watanabe A; Sato J; Hattori R; Terada M; Koashi N; Kozuki T; Maruo A; Morita K; Ogasawara K; Takahashi Y; Watanabe J; Takeuchi K; Fujimura S; Takeda H; Ikeda H; Sato N; Niitsuma K; Saito M; Koshiba S; Kaneko M; Miki M; Nakanowatari S; Honda Y; Chiba J; Takahashi H; Utagawa M; Kondo T; Kawana A; Konosaki H; Aoki Y; Ueda H; Sugiura H; Ichioka M; Goto H; Kurai D; Okazaki M; Yoshida K; Yoshida T; Tanabe Y; Kobayashi S; Okada M; Tsukada H; Imai Y; Honma Y; Nishikawa K; Yamamoto T; Kawai A; Kashiwabara T; Takesue Y; Wada Y; Nakajima K; Miyara T; Toda H; Mitsuno N; Sugimura H; Yoshioka S; Kurokawa M; Munekawa Y; Nakajima H; Kubo S; Ohta Y; Mikasa K; Maeda K; Kasahara K; Koizumi A; Sano R; Yagi S; Takaya M; Kurokawa Y; Kusano N; Mihara E; Kuwabara M; Fujiue Y; Ishimaru T; Matsubara N; Kawasaki Y; Tokuyasu H; Masui K; Negayama K; Ueda N; Ishimaru M; Nakanishi Y; Fujita M; Honda J; Kadota J; Hiramatsu K; Aoki Y; Nagasawa Z; Suga M; Muranaka H; Yanagihara K; Fujita J; Tateyama M; Sunakawa K; Totsuka K
    J Infect Chemother; 2009 Jun; 15(3):156-67. PubMed ID: 19554400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
    Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.